Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q86US8
UPID:
EST1A_HUMAN
Alternative names:
Ever shorter telomeres 1A; Nonsense mediated mRNA decay factor SMG6; Smg-6 homolog; hSmg5/7a
Alternative UPACC:
Q86US8; B7Z874; O94837; Q86VH6; Q9UF60
Background:
Telomerase-binding protein EST1A, also known as Ever shorter telomeres 1A, plays a crucial role in the replication of chromosome termini by being a component of the telomerase ribonucleoprotein complex. It binds to specific telomeric DNA sequences, promoting telomere elongation and has a role in telomere regulation. Additionally, EST1A is involved in nonsense-mediated mRNA decay (NMD), serving as a link to the mRNA degradation machinery and degrading single-stranded RNA.
Therapeutic significance:
Understanding the role of Telomerase-binding protein EST1A could open doors to potential therapeutic strategies.